Literature DB >> 23509406

PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment.

Kristian Tveten1, Thea Bismo Str M1, Knut Erik Berge1, Trond P Leren2.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the LDL receptor (LDLR) at the cell surface and reroutes the internalized LDLR to intracellular degradation. In this study, we have shown that PCSK9-mediated degradation of the full-length 160 kDa LDLR generates a 17 kDa C-terminal LDLR fragment. This fragment was not generated from mutant LDLRs resistant to PCSK9-mediated degradation or when degradation was prevented by chemicals such as ammonium chloride or the cysteine cathepsin inhibitor E64d. The observation that the 17 kDa fragment was only detected when the cells were cultured in the presence of the γ-secretase inhibitor DAPT indicates that this 17 kDa fragment undergoes γ-secretase cleavage within the transmembrane domain. The failure to detect the complementary 143 kDa ectodomain fragment is likely to be due to its rapid degradation in the endosomal lumen. The 17 kDa C-terminal LDLR fragment was also generated from a Class 5 mutant LDLR undergoing intracellular degradation. Thus, one may speculate that an LDLR with bound PCSK9 and a Class 5 LDLR with bound LDL are degraded by a similar mechanism that could involve ectodomain cleavage in the endosome.

Entities:  

Keywords:  cathepsin; cleavage; degradation; endosome; low density lipoprotein

Mesh:

Substances:

Year:  2013        PMID: 23509406      PMCID: PMC3646457          DOI: 10.1194/jlr.M034371

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  46 in total

1.  LDL-receptor structure. Calcium cages, acid baths and recycling receptors.

Authors:  M S Brown; J Herz; J L Goldstein
Journal:  Nature       Date:  1997-08-14       Impact factor: 49.962

2.  Retention of mutant low density lipoprotein receptor in endoplasmic reticulum (ER) leads to ER stress.

Authors:  Stine Sørensen; Trine Ranheim; Kari Solberg Bakken; Trond P Leren; Mari Ann Kulseth
Journal:  J Biol Chem       Date:  2005-10-28       Impact factor: 5.157

3.  Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Authors:  Jamie Cameron; Øystein L Holla; Trine Ranheim; Mari Ann Kulseth; Knut Erik Berge; Trond P Leren
Journal:  Hum Mol Genet       Date:  2006-03-28       Impact factor: 6.150

4.  4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor.

Authors:  Kristian Tveten; Øystein L Holla; Trine Ranheim; Knut E Berge; Trond P Leren; Mari A Kulseth
Journal:  FEBS J       Date:  2007-03-05       Impact factor: 5.542

5.  Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.

Authors:  David Cunningham; Dennis E Danley; Kieran F Geoghegan; Matthew C Griffor; Julie L Hawkins; Timothy A Subashi; Alison H Varghese; Mark J Ammirati; Jeffrey S Culp; Lise R Hoth; Mahmoud N Mansour; Katherine M McGrath; Andrew P Seddon; Shirish Shenolikar; Kim J Stutzman-Engwall; Laurie C Warren; Donghui Xia; Xiayang Qiu
Journal:  Nat Struct Mol Biol       Date:  2007-04-15       Impact factor: 15.369

6.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Authors:  Thomas A Lagace; David E Curtis; Rita Garuti; Markey C McNutt; Sahng Wook Park; Heidi B Prather; Norma N Anderson; Y K Ho; Robert E Hammer; Jay D Horton
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

7.  NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Authors:  Suzanne Benjannet; David Rhainds; Rachid Essalmani; Janice Mayne; Louise Wickham; Weijun Jin; Marie-Claude Asselin; Josée Hamelin; Mathilde Varret; Delphine Allard; Mélanie Trillard; Marianne Abifadel; Angie Tebon; Alan D Attie; Daniel J Rader; Catherine Boileau; Louise Brissette; Michel Chrétien; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

8.  The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.

Authors:  Nasha Nassoury; Daniel A Blasiole; Angie Tebon Oler; Suzanne Benjannet; Josée Hamelin; Vivianne Poupon; Peter S McPherson; Alan D Attie; Annik Prat; Nabil G Seidah
Journal:  Traffic       Date:  2007-04-25       Impact factor: 6.215

9.  The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.

Authors:  Derek E Piper; Simon Jackson; Qiang Liu; William G Romanow; Susan Shetterly; Stephen T Thibault; Bei Shan; Nigel P C Walker
Journal:  Structure       Date:  2007-05       Impact factor: 5.006

10.  Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly.

Authors:  Øystein L Holla; Jamie Cameron; Knut Erik Berge; Trine Ranheim; Trond P Leren
Journal:  BMC Cell Biol       Date:  2007-03-01       Impact factor: 4.241

View more
  9 in total

1.  γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor.

Authors:  KyeongJin Kim; Ira J Goldberg; Mark J Graham; Meenakshi Sundaram; Enrico Bertaggia; Samuel X Lee; Li Qiang; Rebecca A Haeusler; Daniel Metzger; Pierre Chambon; Zemin Yao; Henry N Ginsberg; Utpal B Pajvani
Journal:  Cell Metab       Date:  2018-03-22       Impact factor: 27.287

2.  Site-1 protease-activated formation of lysosomal targeting motifs is independent of the lipogenic transcription control.

Authors:  Sarah Klünder; Jörg Heeren; Sandra Markmann; René Santer; Thomas Braulke; Sandra Pohl
Journal:  J Lipid Res       Date:  2015-06-24       Impact factor: 5.922

3.  PCSK9 is a critical regulator of the innate immune response and septic shock outcome.

Authors:  Keith R Walley; Katherine R Thain; James A Russell; Muredach P Reilly; Nuala J Meyer; Jane F Ferguson; Jason D Christie; Taka-aki Nakada; Chris D Fjell; Simone A Thair; Mihai S Cirstea; John H Boyd
Journal:  Sci Transl Med       Date:  2014-10-15       Impact factor: 17.956

4.  Systematic substrate identification indicates a central role for the metalloprotease ADAM10 in axon targeting and synapse function.

Authors:  Peer-Hendrik Kuhn; Alessio Vittorio Colombo; Benjamin Schusser; Daniela Dreymueller; Sebastian Wetzel; Ute Schepers; Julia Herber; Andreas Ludwig; Elisabeth Kremmer; Dirk Montag; Ulrike Müller; Michaela Schweizer; Paul Saftig; Stefan Bräse; Stefan F Lichtenthaler
Journal:  Elife       Date:  2016-01-23       Impact factor: 8.140

5.  Studies of the autoinhibitory segment comprising residues 31-60 of the prodomain of PCSK9: Possible implications for the mechanism underlying gain-of-function mutations.

Authors:  Lene Wierød; Jamie Cameron; Thea Bismo Strøm; Trond P Leren
Journal:  Mol Genet Metab Rep       Date:  2016-11-17

6.  Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts.

Authors:  My-Anh Nguyen; Tanja Kosenko; Thomas A Lagace
Journal:  J Lipid Res       Date:  2013-12-02       Impact factor: 5.922

7.  Mutation G805R in the transmembrane domain of the LDL receptor gene causes familial hypercholesterolemia by inducing ectodomain cleavage of the LDL receptor in the endoplasmic reticulum.

Authors:  Thea Bismo Strøm; Kristian Tveten; Jon K Laerdahl; Trond P Leren
Journal:  FEBS Open Bio       Date:  2014-03-19       Impact factor: 2.693

8.  Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.

Authors:  Steve Poirier; Hocine Ait Hamouda; Louis Villeneuve; Annie Demers; Gaétan Mayer
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

Review 9.  Statins: a repurposed drug to fight cancer.

Authors:  Wen Jiang; Jin-Wei Hu; Xu-Ran He; Wei-Lin Jin; Xin-Yang He
Journal:  J Exp Clin Cancer Res       Date:  2021-07-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.